Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?

Background: Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. Methods: We performed survival analyses of MDS subtypes by receipt of ICT. Results: 182 MDS were lower IPSS risk and received red blood cell (RBC) transfusions; 63 received ICT. For the entire cohort, receiving ICT independently predicted superior OS in a multivariate analysis (hazard ratio for death 0.3, p = 0.01). Features differing for ICT and non-ICT patients, respectively, were: age; IPSS risk group; number of RBC units transfused; and SF, p <= 0.03 for all. At a median follow up of 76.5 and 28.4 months, 65.1% and 63.0% were alive. Median OS (months) for ICT and non-ICT patients was: RA, 140.9 and 36.3, p = 0.0008; RARS/RARS-t, 133.4 and 73.3, p = 0.02. For RCMD/RCMD-RS, p = NS, however, 3 (20%) had significant erythroid improvement with ICT; other subtypes had small numbers. Discussion: In this retrospective analysis, RA and RARS/RARS-t patients receiving ICT had superior OS to non-ICT patients. These findings should be verified and other MDS subtypes examined in larger prospective analyses.